ETF Holdings Breakdown of SPRY

SPRY institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	28,783	USD 282,073
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	3,620	USD 35,476
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	55,415	USD 543,067
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	55,415	USD 543,067
Total =		143,233	USD 1,403,683

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SPRY

XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47

Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51

Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58

Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG

Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50

Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55

Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56

Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48

Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52

Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)

Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50

Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48

Back to Listing

Disclaimer